News

Marc Robillard, CEO of Tagworks Pharmaceuticals has been invited to speak during the Gordon Research Conference on Organic Reactions and Processes, held from 13-18 July 2014 at Bryant University, Smithfield, RI. In his lecture entitled "In vivo Chemistry for Cancer Imaging and Therapy" Marc Robillard will present the company's R&D …

Together with prof. Tom Quinn of the University of Missouri-Columbia, Tagworks succeeded in securing an Exploratory/Development grant from the US National Institutes of Health (NIH) Innovative Molecular Analysis Technologies (IMAT) program for the project "In vivo metal-free cycloaddition chemistry driven pretargeted cancer radiotherapy". The proposal was ranked in the top …

By modifying the fastest and highly selective click reaction, the inverse-electron-demand-Diels-Alder reaction, Tagworks has achieved selective bioorthogonal release. This holds promise for the chemically triggered release, and thus activation, of drugs from tumor-bound Antibody-Drug Conjugates (ADCs), which would greatly enhance the scope of suitable ADC targets. Published in: Angewandte Chemie …

Tagworks' pretargeting technology can boost tumor/non-tumor ratios compared with conventional radioimmunoimaging and -therapy. Published in Journal Nuclear Medicine 2013, 54, 11, 1989-1995 doi:10.2967/jnumed.113.12.3745

Antibody tags with 10-fold increased reactivity and enhanced in vivo stability - Check the paper on 'Highly reactive trans-cyclooctene tags with improved stability for Diels-Alder chemistry in living systems' published in Bioconjugate Chemistry 2013, 24 ,7, 1210-1217 doi:10.1021/bc400153y

On Wednesday June 12, Tagworks CEO Marc Robillard is a speaker in the "Probes for Oncology: Novel Oncology Probes and Chemistry" session at the SNMMI 2013 in Vancouver.

Top-5 pharma company and Tagworks start collaboration on companion diagnostics.